RxDoctor Payments Data

Gabriel Manzi, MD

Family Medicine · Fort Lauderdale, FLNPI 1306097035

Payments from drug & device makers

$1,096in general payments, 2019–2025

Across 58 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • AbbVie$161
  • Pfizer$157
  • Amgen$110
  • Gilead$60
  • Merck$59
  • plus $324 from 10 others

What the payments were for

  • Food & beverage$1,096100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$225
AbbVie(2 entities)8$161
Pfizer7$157
Amgen6$110
Gilead3$60
Merck4$59
GSK3$54
Lilly USA, LLC3$44
Astellas Pharma US Inc2$41
Boehringer Ingelheim2$38
Dexcom, Inc.2$37
Currax Pharmaceuticals LLC2$35
Exact Sciences1$25
Johnson & Johnson1$25
Novartis1$14
Nalpropion Pharmaceuticals LLC1$13

How this compares

$1,096 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$170,488
Medicare patients
508
Services billed
1,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$122,124
OzempicSemaglutide55$76,920
RybelsusSemaglutide52$72,728
JanuviaSitagliptin Phosphate47$47,702
FarxigaDapagliflozin Propanediol44$33,886
JardianceEmpagliflozin24$33,226
XareltoRivaroxaban19$30,386
TradjentaLinagliptin15$18,735
Breo ElliptaFluticasone/Vilanterol32$17,184
Atorvastatin Calcium693$7,702
VascepaIcosapent Ethyl16$5,999
Repatha SureclickEvolocumab11$5,900
Rosuvastatin Calcium327$5,571
Valsartan191$4,545
Levothyroxine Sodium385$4,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$225$149,648107 claims
PfizerEliquis$157$122,124150 claims
Boehringer IngelheimJardiance, Tradjenta$38$51,96139 claims
MerckJanuvia$59$47,70247 claims
Johnson & JohnsonXarelto$25$30,38619 claims
GSKBreo Ellipta$54$17,18432 claims
AbbVieSynthroid$161$2,04731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →